Arcus Biosciences, INC 8-K filings

Arcus Biosciences stockholders re-elected four Class II directors and ratified the appointment of Ernst & Young LLP.

Arcus Biosciences announced the discontinuation of its Phase 3 STAR-121 study for metastatic non-small cell lung cancer due to futility, and Gilead will not extend its option rights for early-stage pipeline programs.

Arcus Biosciences announced Chief Operating Officer Jennifer Jarrett's resignation, effective March 30, 2026, with her providing advisory services until June 30, 2026.

Arcus Biosciences reported its fourth-quarter and full-year 2025 financial results, highlighting strong casdatifan data and a cash runway extending into late 2028.

Arcus Biosciences amended its loan agreement, gaining access to an additional $150 million tied to clinical and regulatory milestones and extending the maturity date to 2030.

Arcus Biosciences announced the discontinuation of its Phase 3 STAR-221 and Phase 2 EDGE-Gastric studies for advanced gastric and esophageal cancers due to futility.

Arcus Biosciences, Inc. successfully completed a public offering of 15.755 million common shares, raising approximately $269.7 million in net proceeds.

Arcus Biosciences reported Q3 2025 financial results and provided pipeline updates, highlighting strong casdatifan data and a new inflammatory disease portfolio.

Arcus Biosciences announced positive overall survival and efficacy results from its Phase 2 EDGE-Gastric study for advanced gastric and esophageal adenocarcinoma.

Arcus Biosciences presented updated Phase 1/1b data for casdatifan in metastatic clear cell renal cell carcinoma and unveiled new immunology and inflammation programs with clinical studies expected in 2026.

Arcus Biosciences reported a significant revenue increase and break-even net income for Q2 2025, driven by a one-time accounting adjustment, while advancing multiple oncology programs into late-stage clinical trials.

Arcus Biosciences, Inc. announced the results of its annual stockholder meeting, including the election of Class I directors and the ratification of its independent auditor, alongside the approval of executive compensation and a revised non-employee director compensation program.

Arcus Biosciences, Inc. announced updated positive interim data from its Phase 1/1b ARC-20 study, highlighting a 46% confirmed objective response rate for casdatifan plus cabozantinib in patients with clear cell renal cell carcinoma who had progressed on prior immunotherapy.

Arcus Biosciences announced its first-quarter 2025 financial results, highlighting a strong cash position and progress in its clinical-stage pipeline, particularly with casdatifan.

Arcus Biosciences announces positive clinical data for casdatifan, initiation of a Phase 3 study, and a strong cash position of $992 million as of December 31, 2024.

Arcus Biosciences has successfully completed a public offering of common stock, raising approximately $141.6 million to fund research and development activities.

Arcus Biosciences reports Gilead's decision not to exercise its option for casdatifan and releases promising data from the ARC-20 study in metastatic clear cell renal cell carcinoma.

Arcus Biosciences reports the resignation of Merdad Parsey from its Board of Directors and the appointment of Dietmar Berger as his replacement, effective February 6, 2025.

Arcus Biosciences has appointed Richard Markus, M.D., Ph.D., as its new Chief Medical Officer, effective January 31, 2025, while Dimitry Nuyten, M.D., Ph.D., will depart the company on the same date.

Arcus Biosciences announced encouraging clinical trial results for its cancer therapies and a robust cash position of $1.1 billion, extending its operational runway into mid-2027.

Arcus Biosciences reported promising interim data for its investigational drug casdatifan, showing a 25% confirmed objective response rate in heavily pre-treated renal cell carcinoma patients.

Arcus Biosciences has entered into a loan agreement for up to $250 million to support its clinical development programs.

Arcus Biosciences announced its second quarter 2024 financial results, highlighted by $1.0 billion in cash and progress across its oncology pipeline.

Arcus Biosciences held its annual stockholder meeting, elected directors, ratified its auditor, approved executive compensation, and revised its non-employee director compensation program.

Arcus Biosciences reported encouraging interim data from its Phase 2 EDGE-Gastric trial, showing promising efficacy and tolerability for domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal cancers.

Arcus Biosciences reports statistically significant improvements in progression-free and overall survival in a Phase 2 trial for metastatic colorectal cancer using a combination therapy.

Arcus Biosciences announced strong first-quarter 2024 financial results, highlighted by a significant increase in revenue and a robust cash position, alongside key pipeline advancements.

Arcus Biosciences announced its fourth-quarter and full-year 2023 financial results, a $320 million equity investment from Gilead, and provided updates on its clinical pipeline, including strategic changes to its domvanalimab program.

Gilead Sciences has made a $320 million equity investment in Arcus Biosciences, amending their collaboration to accelerate key cancer drug programs and increasing Gilead's ownership stake to 33%.